BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24194908)

  • 1. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.
    Kim SK; Kim H; Lee DH; Kim TS; Kim T; Chung C; Koh GY; Kim H; Lim DS
    PLoS One; 2013; 8(10):e78130. PubMed ID: 24194908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
    Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
    Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
    Liu P; Brown S; Goktug T; Channathodiyil P; Kannappan V; Hugnot JP; Guichet PO; Bian X; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2012 Oct; 107(9):1488-97. PubMed ID: 23033007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.
    Cong J; Wang Y; Zhang X; Zhang N; Liu L; Soukup K; Michelakos T; Hong T; DeLeo A; Cai L; Sabbatino F; Ferrone S; Lee H; Levina V; Fuchs B; Tanabe K; Lillemoe K; Ferrone C; Wang X
    Cancer Lett; 2017 Nov; 409():9-19. PubMed ID: 28864067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
    Raha D; Wilson TR; Peng J; Peterson D; Yue P; Evangelista M; Wilson C; Merchant M; Settleman J
    Cancer Res; 2014 Jul; 74(13):3579-90. PubMed ID: 24812274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
    Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE
    PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine.
    Van den Broeck A; Gremeaux L; Topal B; Vankelecom H
    BMC Cancer; 2012 Aug; 12():354. PubMed ID: 22894607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.
    Rasheed ZA; Yang J; Wang Q; Kowalski J; Freed I; Murter C; Hong SM; Koorstra JB; Rajeshkumar NV; He X; Goggins M; Iacobuzio-Donahue C; Berman DM; Laheru D; Jimeno A; Hidalgo M; Maitra A; Matsui W
    J Natl Cancer Inst; 2010 Mar; 102(5):340-51. PubMed ID: 20164446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.
    Bhagwandin VJ; Bishop JM; Wright WE; Shay JW
    PLoS One; 2016; 11(2):e0148807. PubMed ID: 26859746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
    Jimeno A; Feldmann G; Suárez-Gauthier A; Rasheed Z; Solomon A; Zou GM; Rubio-Viqueira B; García-García E; López-Ríos F; Matsui W; Maitra A; Hidalgo M
    Mol Cancer Ther; 2009 Feb; 8(2):310-4. PubMed ID: 19174553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram/copper targets stem cell-like ALDH
    Jin N; Zhu X; Cheng F; Zhang L
    J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.